p4

Cambridge Healthtech Institute’s 10th Annual

Protein Aggregation and Emerging Analytical Tools

January 17-18, 2019

 

The popular 10th Annual Protein Aggregation and Emerging Analytical Tools conference covers latest trends, challenges and solutions in understanding, characterization and mitigation of problems generated by protein aggregation in biopharmaceuticals. This conference will feature in-depth case studies, new and unpublished data and interactive discussions on immunogenicity of aggregates, mechanisms of aggregation, new tools for detection and quantitation of aggregates, and how the data is used in regulatory filings. It will also discuss mechanistic understanding of protein aggregation and present case studies on prevention of particle formation by engineering and formulation approaches, aggregation in ADCs, bipecifics, impact of aggregation on production, aggregates as a factor for immunogenicity, and approaches for improvement of biophysical properties of protein solutions.

Final Agenda

5:45 - 8:45 Recommended Dinner Short Courses*

SC3: Protein Aggregation: Mechanism, Characterization and Consequences

Click here for more details.

*Separate registration required

THURSDAY, JANUARY 17

7:45 am Registration and Morning Coffee

Chemical Modifications, Protein Polymorphism and Immunogenicity

8:10 Organizer’s Welcome Remarks

Nandini Kashyap, Conference Director, Cambridge Healthtech Institute

8:15 Chairperson’s Opening Remarks

Thomas Laue, PhD, Professor Emeritus, Molecular, Cellular and Biomedical Sciences, University of New Hampshire



KEYNOTE PRESENTATION

8:20 Chemical Protein Modifications and Immunogenicity Risks

Christian Schöneich, PhD, Takeru Higuchi Distinguished Professor and Chair, Department of Pharmaceutical Chemistry, The University of Kansas

Chemical modifications can play an important role in the immunogenicity of proteins. We have designed experiments to test whether specific chemical protein modifications induced by light are immunogenic. Peptides derived from a light-exposed humanized monoclonal antibody were fractionated, and these fractions injected into transgenic mice designed to tolerate native human IgG. Specific peptide fractions showed immunogenic responses, and chemical modifications present in these fractions were characterized by HPLC-MS/MS analysis.

FEATURED PRESENTATION

9:00 Protein Polymorphism, Heterogeneity and the Immunogenicity of Biotherapeutics

Roy Jefferis, PhD, MRCP, FRCPath, DSc, Emeritus Professor, Institute of Immunology & Immunotherapy, University of Birmingham

Administration of biotherapeutic drug may be considered: 1) to introduce/supplement a deficit in a natural (self) protein/glycoprotein (P/GP); 2) to manipulate/eliminate the activity of a self-molecule/cell. Clinical experience shows that a proportion of patients produce an anti-therapeutic antibody drug (ATA) immune response. This may be due to: 1) absence of the natural molecule or exposure to an unmatched polymorphic variant; 2) exposure to a molecule lacking structural fidelity with a self P/GP.

9:30 Next Steps in Biophysical Characterization and Screening: RPC/IEX-MALS and HT-SLS

Kevin McCowen, Application Scientist, Wyatt Technology

SEC-MALS and high-throughput DLS (HT-DLS) are widely implemented across biopharma to characterize molar mass, aggregation, oligomerization and fragmentation, and to screen candidates and formulations for aggregation and stability. Recent extensions of light scattering will be presented: a light-scattering plate reader that measures both dynamic and static light scattering to determine size, molar mass, kD, A2, thermal stability and viscosity; and the use of multi-angle light scattering with reversed-phase and ion-exchange chromatography.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

Mechanistic Understanding, Prediction and Characterization of Protein Aggregation

11:00 IgG Charge

Thomas Laue, PhD, Professor Emeritus, Molecular, Cellular and Biomedical Sciences, University of New Hampshire

Charge is a fundamental property of practical and biological importance. ZDHH has been measured in formulation (pH 5) and physiological (PBS) solvent for three different IL-13-specific mAbs. For each mAb, ZDHH has been measured for four IgG subclasses, as well as their Fc and F(ab’)2 fragments. Also, the distribution of ZDHH has been determined for human poly-IgG in PBS. The results illustrate how little is known about protein charge.

11:30 PANEL DISCUSSION: Protein Modifications and Immunogenicity Risks

  • Chemical modification and relationship to immunogenicity
  • In vitro and in vivo detection and analysis
  • Clinical consequences

Moderator:

Thomas Laue, PhD, Professor Emeritus, Molecular, Cellular and Biomedical Sciences, University of New Hampshire

Panelists:

Christian Schöneich, PhD, Takeru Higuchi Distinguished Professor and Chair, Department of Pharmaceutical Chemistry, The University of Kansas

Wei Wang, PhD, Senior Scientist, Biologics Development, Bayer U.S. LLC

Peter M. Ihnat, PhD, Principal Scientist, Biologics Preformulation and Drug Delivery, Abbvie Bioresearch Center

12:00 pm Session Break

12:10 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:10 Ice Cream Break in the Exhibit Hall with Poster Viewing

Mechanistic Understanding, Prediction and Characterization of Protein Aggregation (Cont.)

2:15 Chairperson’s Remarks

Christian Schöneich, PhD, Takeru Higuchi Distinguished Professor and Chair, Department of Pharmaceutical Chemistry, The University of Kansas

2:20 Investigating the Mechanism of Protein Aggregation and Subvisible Particle Formation Mediated by Solid-Liquid Interfaces

Cavan Kalonia, PhD, Scientist, Late Stage Formulation Sciences, MedImmune

Physical degradation and aggregation of proteins at solid-liquid interfaces can negatively impact the manufacturability, shelf-life stability, and administration of protein therapeutics. Despite the critical impact of solid-liquid interfaces on protein stability, the mechanisms of interfacial degradations remain poorly understood and highly speculative in the pharmaceutical literature. In this work, we implement and develop state of the art metrology and modeling tools to investigate protein interfacial degradation at pharmaceutically relevant surfaces.

2:50 Mechanism, Consequence and Control of Protein Opalescence

Wei Wang, PhD, Senior Scientist, Biologics Development, Bayer U.S. LLC

Protein opalescence is a commonly-observed phenomenon. It is often accompanied by phase separation, especially at high protein concentrations. Both protein opalescence and phase separation are undesirable physical properties in the development of a successful protein pharmaceutical product. This presentation discusses the mechanism of protein opalescence, its potential consequences, and various means of controlling protein opalescence.

3:20 Sponsored Presentation (Opportunity Available)

3:35 Networking Refreshment Break

Formulation, Process and Manufacturing Strategies to Overcome Aggregation

4:00 Formulation and Container Closure System Strategies for Biopharmaceuticals with Higher Stability

Susumu Uchiyama, PhD, Professor, Department of Biotechnology, Graduate School of Engineering, Osaka University

We have identified causes of protein aggregation in biopharmaceuticals and attempted to optimize formulation and container closure system to reduce the protein aggregates. Secondary virial coefficient can be effective parameter for the prediction of aggregation tendency. Meanwhile, appropriate selection of barrel material is necessary for biopharmaceuticals with better quality. Silicon oil free polymer-based syringe is most suitable for biopharmaceuticals. All together formulation and container closure system strategies will be introduced.

4:30 Aggregation Mechanisms and Molecular Profiling of Therapeutic Antibodies

Peter M. Ihnat, PhD, Principal Scientist, Biologics Preformulation and Drug Delivery, Abbvie Bioresearch Center

Isothermal chemical denaturation was used to calculate the free energies of unfolding as a function of concentration and determine the mechanisms of oligomerization for a series of IgG1 antibodies. Most of the IgG1s favored the native state mechanism of association which was sensitive to pH. The mechanisms were correlated with thermal analysis, aggregation kinetics and structural attributes to illustrate screening and risk assessment of IgG1 candidates.

5:00 Novel Biopharmaceutical Compositions to Reduce the Rate of Aggregation

Jan Jezek, PhD, CSO, Research & Development, Arecor, Ltd.

Despite considerable progress in candidate screening and formulation approaches, protein aggregation during manufacturing, storage and use remains one of the key challenges of biopharmaceutical development, particularly for a number of new modalities such as bispecific antibodies. This talk will show on several case studies how novel and unconventional formulations can significantly decrease the rate of aggregation alongside other degradation pathways and enable development of competitive patient-friendly products.

5:30 Close of Day

FRIDAY, JANUARY 18

8:00 am Registration

8:00 BuzZ Sessions with Continental Breakfast

Protein therapeutics is a fast-growing global market. As the science improves, so does the complexity of the R&D organization. Ensuring product quality plus speed to market requires insights from stakeholders working across the stages of protein science R&D. Join experts representing this PepTalk pipeline, peers, and colleagues for an interactive roundtable discussion. Topics include highlights from the week’s presentations, new technologies and strategies, challenges, and future trends.


Moderator: Thomas Laue, PhD, Professor Emeritus, Molecular, Cellular and Biomedical Sciences, University of New Hampshire

 

Emerging Analytical Tools for Detection of Protein Aggregation

9:00 Chairperson’s Remarks

Jan Jezek, PhD, CSO, Research & Development, Arecor, Ltd.

9:05 Novel Analytical Approaches for Mechanistic Understanding of Protein Aggregation

Ulla Elofsson, PhD, Associate Professor, Senior Scientist, RISE Research Institutes of Sweden

The use of scattering techniques (electrons, neutrons) to investigate aggregation mechanisms at high resolution in space and time will be explored. Predictive methods are built on this knowledge in combination with stability data generated by traditional (long term stability studies) and other techniques such as DLS and AF4. As an example, we will present methods to study surface induced protein aggregation.

9:35 Water Proton NMR for in situ Detection of Protein Aggregation

Yihua Bruce Yu, PhD, Professor, Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy

The water proton (1H2O) NMR signal is sensitive to protein aggregation. Compared with conventional analytical techniques, 1H2O NMR can be performed on protein solutions inside sealed containers and thereby is applicable to both drug substance and drug products. 1H2O NMR can detect both small (nanometer sized) and large (micrometer) aggregates. 1H2O NMR can be implemented using benchtop NMR spectrometers; data collection and analysis takes 1-2 min per sample.

10:05 Development Strategy of Fibril-Prone Peptide Therapeutics: Aggregation Kinetics, Predictive Methods, and Detection Methods

Jingtao Zhang, PhD, Principal Scientist, Pharmaceutical Sciences, Merck Research Laboratories

Peptide aggregation such as fibrillation presents significant challenges for DS and DP development of peptide therapeutics. Different development criteria and control strategy are required for fibril development in contrast to protein aggregation. The unique nature of fibril also presents significant challenges in the analytical development, especially in aggregation measurement. Approaches to close gaps in these areas will be shared in the presentation, which includes the investigation on the aggregation kinetics of a fibril-prone peptide, the projection of physical stability shelf-life, and the development of highly sensitive characterization methods for fibrils.

10:35 Networking Coffee Break

11:00 Characterizing and Inhibiting Glucagon Fibrillation

Elizabeth M. Topp, PhD, Dane O. Kildsig Chair and Department Head, Department of Industrial and Physical Pharmacy, Purdue University

Glucagon, a peptide hormone, is currently marketed in lyophilized form for treating severe hypoglycemia. The lyophilized form is necessary because glucagon rapidly fibrillates in solution. This presentation summarizes computational and experimental studies of the mechanisms of glucagon fibrillation and presents novel glucagon derivatives that resist fibrillation.

11:30 Investigation of Oxidation Potential of Protein Formulation Excipients and Processes Using Dansyl-Methionine

Lin M. Luis, Senior Research Associate, Late Stage Pharmaceutical Development, Genentech

Proteins and excipients are continually exposed to internal and external oxidants. The external factors and processes that give rise to these oxidants include light, metals, cavitation, etc. We have results showing dansyl-methionine is a good protein surrogate that is capable of picking up, irreversibly, very low amount of oxidation due to peroxides from formulation excipients and processes.

12:00 pm Conference Wrap-Up

Thomas Laue, PhD, Professor Emeritus, Molecular, Cellular and Biomedical Sciences, University of New Hampshire

12:30 Close of Conference

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean





Premier Sponsors

Fujifilm-Diosynth-Logo

GE_Healthcare